Optimizing Patient Outcomes in High-Risk HR+, HER2- Early-Stage Breast Cancer

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide a comprehensive analysis of risk stratification in high-risk HR+/HER2- early-stage breast cancer, clinical approaches with high-risk breast cancer, recent trial data with CDK4/6 inhibitors, and strategies for managing toxicities for treatment continuity in the management of HR+/HER2- early-stage breast cancer, offering valuable insights to optimize patient care.

EP. 1: HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification

March 27th 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, discuss the biological and pathological risk factors influencing breast cancer development, treatment, and risk stratification.

EP. 2: NCCN Guidelines vs Real-World Practice: Risk Stratifying HR+/HER2- Early Breast Cancer

April 3rd 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, examine the NCCN guidelines compared to real-world evidence, particularly in the treatment of menopausal, pre-menopausal, and high-risk early-stage HR+/HER2- patients.

EP. 3: 5-Year Data from the MonarchE Trial Investigating Abemaciclib in HR+, HER2- High-Risk, Early Breast Cancer

April 10th 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, provide an in-depth analysis of the randomized phase III monarchE trial, which focused on Abemaciclib in high-risk early-stage HR+, HER2- breast cancer, offering insights into recurrence rates, progression-free survival, and distant disease-free survival outcomes for patients.

EP. 4: The Evolving Treatment Landscape with CDK4/6 Inhibitors in Early HR+/HER2- Breast Cancer

April 17th 2024

Medical experts analyze the impact of CDK4/6 inhibitors in early-stage HR+/Her2- breast cancer patients, and how recent clinical trial data translates to the real-world clinical application of these agents.

EP. 5: AE Management with CDK4/6 Inhibitors: Strategies for Treatment Continuity and Optimal Patient Outcomes

April 24th 2024

Medical professionals discuss proactive symptom management for adverse events like diarrhea, hair thinning, cytopenia, and neutropenia, offering guidance on dose reduction and treatment holds to optimize patient outcomes while minimizing adverse effects.

EP. 6: Shared Decision Making and Multidisciplinary Collaboration in the Evolving HR+/HER2- Early-Stage Breast Cancer Landscape

May 1st 2024

Hope Rugo, MD, FASCO, and Naomi Dempsey, MD, emphasize the importance of shared decision-making, comprehensive data, and well-informed multidisciplinary team collaboration in delivering high-quality, patient-centered care, while highlighting the benefits of tailored adjuvant therapies.